How do I buy Avalo Therapeutics, Inc. Common Stock (AVTX) stock?

Buying Avalo Therapeutics, Inc. Common Stock (AVTX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "AVTX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy AVTX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for AVTX on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Avalo Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Avalo Therapeutics, Inc. Common Stock (AVTX) pay dividends?

At the moment, Avalo Therapeutics, Inc. Common Stock (AVTX) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track AVTX's performance via the price chart in the Gotrade app.

Is buying AVTX on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy AVTX?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if AVTX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Avalo Therapeutics, Inc. Common Stock (AVTX) Stock Price: Nov 11 Close $8.51

Latest news

Investors Business Daily

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

AVTXMay 6, 2026

Investors Business Daily

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

AVTX

Stocktwits

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results

AVTXMay 5, 2026

Stocktwits

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results

AVTX

Zacks Investment Research

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

AVTXApril 3, 2026

Zacks Investment Research

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

AVTX

Zacks Investment Research

About Avalo Therapeutics, Inc. Common Stock

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

SectorHealthcare

IndustryBiotechnology

Employees33

CEODr. Garry A. Neil M.D.

IPO DateNov 13, 2015

HeadquartersWayne, PA

Key Executives

Name	Title	Year Born
Dr. Garry A. Neil M.D.	President, CEO & Director	1954
Dr. Solomon H. Snyder M.D.	Founder and Chairman of Scientific Advisory Board	1939
Mr. Christopher Ryan Sullivan CPA	CFO & Head of Investor relations	1984
Dr. Mittie Doyle FACR, M.D.	Chief Medical Officer	1965
Mr. Taylor Boyd	Chief Business Officer	1989
Dr. Barbara S. Slusher Ph.D.	Founder and Member of Scientific Advisory Board	1965
Mr. Paul C. Varki J.D., M.P.H	Chief Legal Officer	1973
Ms. Ashley Ivanowicz	Senior Vice President of Human Resources	—
Dr. Dino C. Miano Ph.D.	Senior Vice President of CMC & Technical Operations	—
Ms. Jennifer Riley	Chief Strategy Officer	1975

Fundamentals

Valuation

Price-to-sales ratio2,156.25

Price-to-book value0.95

Profitability

Return on Equity-34.00%

Return on Assets-30.00%

Return on Sales-149976.00%

EBITDA$-88.42M

Trading

Average volume3,014,580

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 42.39
MACD 12/26/9: -1.62
EMA 9 of MACD: -1.93
MACD histogram: 0.31
SMA 50: $12.78; Price below SMA 50
EMA 50: $11.71; Price below EMA 50
SMA 200: $15.70; Price below SMA 200
EMA 200: $15.03; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

4 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Hold

50% Buy

50% Hold

0% Sell

Analyst price target

Low: $10.00
Average: $15.00
High: $20.00

Guggenheim

Yatin Suneja

Hold

Target price

-

HC Wainwright & Co.

Mitchell S. Kapoor

Hold

Target price

-

Wedbush

Robert Driscoll

Buy

Target price

$20.00

BTIG

Julian Harrison

Buy

Target price

$10.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026			-17.0	-19.8	+16.3	+17.3	+5.6	+7.1	-19.1	-52.0	+16.3

Compare stocks

AVTX

Buy AVTX

Market cap

$492.07M

-

Price / Earnings ratio

-4.70

-

Price / Sales ratio

2,156.25

-

Dividend yield

0.00%

-

Average volume

3,014,580

-

Earnings per share

$-2.52

-

Avalo Therapeutics, Inc. Common Stock (AVTX) Stock

Key stats

Compare with AVTX

Recent news

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

New Strong Buy Stocks for November 27th

New Strong Buy Stocks for November 27th

3 Penny Stocks To Buy For Under $1, Are They Worth The Risk?

3 Penny Stocks To Buy For Under $1, Are They Worth The Risk?

The 7 Best Biotech Stocks for Personalized Medicine Investors

The 7 Best Biotech Stocks for Personalized Medicine Investors

About Avalo Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade